An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Administered By

Contributors

Start/End

  • September 15, 2015 - September 14, 2016